DE69821624T2 - 9-cis-RETINSÄURE FÜR ZELLVERMITTELTE IMMUNKRANKHEITEN - Google Patents

9-cis-RETINSÄURE FÜR ZELLVERMITTELTE IMMUNKRANKHEITEN Download PDF

Info

Publication number
DE69821624T2
DE69821624T2 DE69821624T DE69821624T DE69821624T2 DE 69821624 T2 DE69821624 T2 DE 69821624T2 DE 69821624 T DE69821624 T DE 69821624T DE 69821624 T DE69821624 T DE 69821624T DE 69821624 T2 DE69821624 T2 DE 69821624T2
Authority
DE
Germany
Prior art keywords
eczema
cis
use according
retinoic acid
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69821624T
Other languages
German (de)
English (en)
Other versions
DE69821624D1 (de
Inventor
Werner Bollag
Fritz Ott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Basilea Pharmaceutica AG
Original Assignee
Basilea Pharmaceutica AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8227266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69821624(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Basilea Pharmaceutica AG filed Critical Basilea Pharmaceutica AG
Application granted granted Critical
Publication of DE69821624D1 publication Critical patent/DE69821624D1/de
Publication of DE69821624T2 publication Critical patent/DE69821624T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69821624T 1997-08-23 1998-08-18 9-cis-RETINSÄURE FÜR ZELLVERMITTELTE IMMUNKRANKHEITEN Expired - Lifetime DE69821624T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97114651 1997-08-23
EP97114651A EP0908179A1 (en) 1997-08-23 1997-08-23 Treatment of cell-mediated immune diseases
PCT/EP1998/005236 WO1999009969A1 (en) 1997-08-23 1998-08-18 Treatment of cell-mediated immune diseases

Publications (2)

Publication Number Publication Date
DE69821624D1 DE69821624D1 (de) 2004-03-18
DE69821624T2 true DE69821624T2 (de) 2004-09-23

Family

ID=8227266

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69821624T Expired - Lifetime DE69821624T2 (de) 1997-08-23 1998-08-18 9-cis-RETINSÄURE FÜR ZELLVERMITTELTE IMMUNKRANKHEITEN

Country Status (18)

Country Link
US (2) US6589989B1 (https=)
EP (2) EP0908179A1 (https=)
JP (1) JP3522220B2 (https=)
KR (1) KR100596260B1 (https=)
CN (1) CN1136845C (https=)
AT (1) ATE259224T1 (https=)
AU (1) AU739440B2 (https=)
BR (1) BRPI9811989B8 (https=)
CA (1) CA2301907C (https=)
DE (1) DE69821624T2 (https=)
DK (1) DK1007020T3 (https=)
ES (1) ES2214729T3 (https=)
NO (1) NO327141B1 (https=)
NZ (1) NZ502812A (https=)
PT (1) PT1007020E (https=)
RU (1) RU2238083C2 (https=)
TR (1) TR200000488T2 (https=)
WO (1) WO1999009969A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541469B2 (en) * 1997-08-23 2013-09-24 Glaxo Group Limited Treatment of cell-mediated immune diseases
US20020031539A1 (en) * 2000-08-30 2002-03-14 The Brigham And Women's Hospital, Inc. Oxidized forms of retinoic acid as ligands for peroxisome proliferator activated receptor gamma
DE10255861A1 (de) * 2002-11-29 2004-06-17 Axxima Pharmaceuticals Ag Gegen Hepatitis C-Virusinfektionen nützliche Verbindungen und Substanzen
FR2834216B1 (fr) * 2001-12-27 2004-04-30 Pharmascience Lab Composition cosmetique ou pharmaceutique comprenant au moins une oxazoline pour inhiber la migration des cellules de langerhans, et ses utilisations
JP2004020220A (ja) * 2002-06-12 2004-01-22 Pioneer Electronic Corp 通信システム及び方法、通信端末装置、通信センタ装置、並びにコンピュータプログラム
TW579640B (en) * 2002-10-23 2004-03-11 Veutron Corp Light gathering device of scanner
EP1527774A1 (en) * 2003-11-03 2005-05-04 Basilea Pharmaceutica AG New formulation for retinoid-containing soft gelatin capsules
US20040242704A1 (en) 2003-03-14 2004-12-02 University Of Washington, Techtransfer - Invention Licensing Stabilized mutant opsin proteins
JP4563997B2 (ja) 2003-04-11 2010-10-20 エフ．ホフマン−ラ ロシュ アーゲー ９−シスレチノイン酸の調製方法
US7122751B1 (en) * 2004-01-16 2006-10-17 Cobalt Flux Switch apparatus
US20080274193A1 (en) * 2004-01-23 2008-11-06 Japan Science And Technology Agency Retinoic Acid-Containing Antidiabetic Agent
BRPI0511396B1 (pt) 2004-06-18 2021-07-27 University Of Washington Uso de 9-cis-retinil éster e uso de um derivado de retinal sintético
AU2012216808B2 (en) * 2004-06-18 2015-04-30 University Of Washington Retinal derivatives and methods for the use thereof for the treatment of visual disorders
AU2015207903B2 (en) * 2004-06-18 2017-08-17 University Of Washington Retinal derivatives and methods for the use thereof for the treatment of visual disorders
JP5042839B2 (ja) 2005-09-09 2012-10-03 有限会社ケムフィズ 腸疾患の予防及び／又は治療のための医薬
JP6022746B2 (ja) 2008-02-11 2016-11-09 ユニヴァーシティ オブ ワシントン 加齢関連性網膜機能不全の治療及び予防方法
US8580278B2 (en) * 2009-06-03 2013-11-12 Trustees Of Dartmouth College Nutraceutical composition and methods for preventing or treating multiple sclerosis
RU2546005C2 (ru) 2009-09-15 2015-04-10 Кью Эл Ти ИНК. Фармацевтические составы, содержащие 9-цис-ретиниловые сложные эфиры в липидном наполнителе
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
US9173856B2 (en) 2010-04-19 2015-11-03 Qlt Inc. Therapeutic regimen and methods for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency
WO2012125724A1 (en) 2011-03-14 2012-09-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of proliferative disorders
WO2012149334A2 (en) 2011-04-27 2012-11-01 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
CN102247348A (zh) * 2011-05-23 2011-11-23 天津拓飞生物科技有限公司 9-顺式维甲酸在制备治疗糖尿病皮肤溃疡的药物中的应用
WO2012162698A1 (en) * 2011-05-26 2012-11-29 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment of immune disorders
EP2731617A4 (en) 2011-07-12 2015-07-01 Brigham & Womens Hospital LIPID-BASED PSA COMPOSITIONS, METHOD FOR THEIR INSULATION AND USE METHOD THEREFOR
CA2865935C (en) 2012-03-01 2021-12-14 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
US9730941B2 (en) 2012-06-07 2017-08-15 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of Pin1
KR102138561B1 (ko) 2012-08-17 2020-07-28 바스프 에스이 올레핀계 화합물의 이성질화
US9221854B2 (en) 2012-08-17 2015-12-29 Basf Se Isomerization of olefinic compounds
US20150202172A1 (en) * 2014-01-22 2015-07-23 Glaxo Group Limited Novel method of use
WO2016011268A1 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Atra for modulating pin1 activity and stability
WO2016011265A2 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Biomarkers for pin1-associated disorders
US10548864B2 (en) 2015-03-12 2020-02-04 Beth Israel Deaconess Medical Center, Inc. Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
JP6918365B2 (ja) 2015-08-19 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 脂質化ｐｓａ組成物および方法
EP3484441A4 (en) 2016-07-15 2020-03-18 President and Fellows of Harvard College GLYCOLIPID COMPOSITIONS AND METHOD FOR USE
CN113499335B (zh) * 2021-07-13 2023-06-20 中国人民解放军军事科学院军事医学研究院 一种靶向自噬融合治疗神经退行性疾病的药物
WO2025108208A1 (zh) * 2023-11-21 2025-05-30 南京纽邦生物科技有限公司 用于改善或维持皮肤、毛囊、头皮或毛发健康的方法和组合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525635A (en) * 1986-02-04 1996-06-11 Moberg; Sven Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof
US5093360A (en) * 1989-04-07 1992-03-03 Yu Ruey J Retinal, derivatives and their therapeutic use
US5057501A (en) * 1990-03-13 1991-10-15 Dermatologic Research Corporation Methods for treatment of papulosquamous and eczematous diseases
US5932622A (en) * 1991-12-18 1999-08-03 The Salk Institute For Biological Studies Method for in vivo modulation of non-malignant skin-related processes with 9-cis-retinoic acid
KR100274101B1 (ko) 1992-01-22 2000-12-15 프리돌린 클라우스너, 롤란드 비. 보레르 9-시스 레틴산을 함유하는 약제학적 조성물
US5750570A (en) * 1992-03-31 1998-05-12 The Regents Of The University Of Michigan Method of treatment of hyperpigmentation in black skin with retinoic acid and method of lightening black skin with retinoic acid
CA2093577C (en) 1992-05-07 2006-01-03 Michael Klaus Alkyl or alkoxy substituted s-heterocyclic retinoids
TW272187B (https=) * 1992-05-20 1996-03-11 Hoffmann La Roche
WO1994022818A1 (en) * 1993-04-05 1994-10-13 Pfizer Inc. Method for the preparation of 9-cis retinoic acid
US5457129A (en) * 1993-05-17 1995-10-10 Research Development Foundation Inhibition of nitric oxide production by retinoic acid
FR2717686B1 (fr) * 1994-03-22 1996-06-28 Fabre Pierre Cosmetique Composition dermo-cosmétologique et procédé de préparation.
DE4415204A1 (de) * 1994-04-30 1995-11-02 Carl Heinrich Dr Weischer Neue Retinol (Vitamin A) -Derivate, deren Herstellung und Verwendung als Arzneimittel und Kosmetika
FR2728790B1 (fr) * 1994-12-29 1997-01-24 Cird Galderma Composition modulant l'apoptose comprenant du methonial ou tout facteur influencant le taux intracellulaire de methonial
US5721103A (en) * 1994-12-30 1998-02-24 Ligand Pharmaceuticals Incorporated Trienoic retinoid compounds and methods
US5837728A (en) * 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
FR2735367B1 (fr) * 1995-06-19 1997-07-18 Cird Galderma Utilisation de ligands specifiques des recepteurs rxrs
FR2752734B1 (fr) * 1996-09-02 1998-11-06 Cird Galderma Utilisation de retinoides pour la preparation d'un medicament destine a traiter les affections liees a une surexpression de vegf
US5994081A (en) * 1998-04-27 1999-11-30 Incyte Pharamaceuticals, Inc. Human keratins
US20030105031A1 (en) * 2001-11-06 2003-06-05 Rosenbloom Richard A. Methods for the treatment of skin disorders

Also Published As

Publication number Publication date
WO1999009969A1 (en) 1999-03-04
NO327141B1 (no) 2009-05-04
AU9435698A (en) 1999-03-16
ES2214729T3 (es) 2004-09-16
EP0908179A1 (en) 1999-04-14
CA2301907C (en) 2009-02-10
JP3522220B2 (ja) 2004-04-26
ATE259224T1 (de) 2004-02-15
NO20000870L (no) 2000-02-22
TR200000488T2 (tr) 2000-07-21
BRPI9811989B8 (pt) 2021-05-25
BRPI9811989B1 (pt) 2015-12-15
RU2238083C2 (ru) 2004-10-20
PT1007020E (pt) 2004-05-31
NO20000870D0 (no) 2000-02-22
NZ502812A (en) 2002-05-31
KR100596260B1 (ko) 2006-07-03
JP2003526595A (ja) 2003-09-09
CA2301907A1 (en) 1999-03-04
US6589989B1 (en) 2003-07-08
KR20010023186A (ko) 2001-03-26
DK1007020T3 (da) 2004-06-07
BR9811989A (pt) 2000-09-05
CN1268886A (zh) 2000-10-04
CN1136845C (zh) 2004-02-04
AU739440B2 (en) 2001-10-11
EP1007020B1 (en) 2004-02-11
US20040039056A1 (en) 2004-02-26
DE69821624D1 (de) 2004-03-18
EP1007020A1 (en) 2000-06-14

Similar Documents

Publication Publication Date Title
DE69821624T2 (de) 9-cis-RETINSÄURE FÜR ZELLVERMITTELTE IMMUNKRANKHEITEN
EP0607231B1 (de) Verwendung einer emulsion, zur herstellung eines arzneimittels zur i.v.-verabreichung zur behandlung von hauterkrankungen
DE69835441T2 (de) Behandlung von t-helfer zell typ 2 vermittelten immunkrankheiten mit retinoid antagonisten
DE69027057T2 (de) Retinal, dessen Derivate und deren therapeutische Verwendung
DE60000133T2 (de) Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen
DE69328910T2 (de) Verwendung von 9-cis-Retinsäure sowie ihre Salze und Ester, zur Behandlung von Epitheltumore
DE3686325T2 (de) Hydratierte lipidische lamellare phasen oder liposome mit retinoid oder deren analoga wie karotenoid enthaltende dermatologische, pharmazeutische oder kosmetische zusammensetzung.
DE69520041T2 (de) Arzneimittel auf der basis von einer synergistischen mischung von metronidazol und clinamicin
DE69612755T2 (de) Triglyceride und ethylester von phenylalkansäuren und phenylalkensäuren zur behandlung verschiedener erkrankungen
EP0582239A1 (de) Pharmazeutische und/oder kosmetische Zubereitung sowie die Verwendung einer derartigen Zubereitung
DE2128462C2 (de) Arzneimittel auf Basis von Vitamin-A-Säure-Isomeren
DE60004786T2 (de) Verfahren und zusammensetzung zur behandlung von akne
US3934028A (en) Acne and psoriasis treatment with retinoic acid analogs
DE68926115T2 (de) Verfahren zur behandlung von akne
US4021573A (en) Psoriasis treatment with retinoic acid analogs
DE69517050T2 (de) Verfahren zur stabilisation der polyungesättigten fettsäuren und verwendung dieser stabilisierten produkten in therapie und in kosmetologie
CH654287A5 (de) Verbindungen und kompositionen zur reduktion der sebumsekretion.
DE69018570T2 (de) Wasserlösliche Vitamin A-Zubereitungen und deren Verwendung bei der Hautbehandlung.
DE2401450A1 (de) Pharmazeutische zusammensetzung zur linderung von hautproliferationserkrankungen
DE60018438T2 (de) Pharmazeutische und/oder kosmetische zusammensetzungen
US8541469B2 (en) Treatment of cell-mediated immune diseases
DE19629802A1 (de) Arzneimittel zur Behandlung von Neuropathien
EP0207421B1 (de) Verwendung eines Retinoids zur Herstellung eines antikeratinisierenden Arzneimittels
EP0009793A2 (de) Pharmazeutisches Mittel, enthaltend 2-(Retinyliden)-malonsäurederivat, Verfahren zu seiner Herstellung und Verwendung
DE69906091T2 (de) Verwendung von lithium-gluconat zur herstellung eines arzneimittels zur behandlung von herpes und seborrhoischer dermatitis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition